PD-L1 inhibitors can directly block the interaction between PD-L1 on tumor cells and PD-1 on T cells, retaining the regulatory effect of PD-L2 on immune response, making them more specific in inhibiting tumor cell immune evasion. Here, CD274 is linked to neoplasm.